



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



C12 Galactosylceramide (d18:1/12:0)

Item No. 24347

CAS Registry No.: 41613-14-3
Formal Name: N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-dodecanamide

Synonyms: N-dodecanoyl-β-D-Galactosylceramide, Galactosylceramide (d18:1/12:0), GalCer(d18:1/12:0)

MF: C₃₆H₆₉NO₈


FW: 643.9

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C12 Galactosylceramide (d18:1/12:0) is supplied as a solid. A stock solution may be made by dissolving the C12 galactosylceramide (d18:1/12:0) in the solvent of choice. C12 Galactosylceramide (d18:1/12:0) is soluble in organic solvents such as ethanol and methanol, which should be purged with an inert gas.

Description

C12 Galactosylceramide is a bioactive sphingolipid.¹⁻³ It inhibits IL-4 production by 53.84% in EL4 T cells when used at a concentration of 10 μM.¹ C12 Galactosylceramide reduces the growth of human papillomavirus type 16-associated tumors in mice and reduces tumor recurrence following surgical removal or chemotherapy.² It also reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus.³

References

1. Park, J., Li, Q., Chang, Y.T., *et al.* Inhibitory activity of a ceramide library in interleukin-4 production from activated T cells. *Bioorg. Med. Chem.* **13(7)**, 2589-2595 (2005).
2. Simova, J., Indrova, M., Bieblova, J., *et al.* Therapy for minimal residual tumor disease: β-Galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy. *Int. J. Cancer* **126(12)**, 2997-3004 (2010).
3. Morshed, S.R., Takahashi, T., Savage, P.B., *et al.* β-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. *J. Clin. Immunol.* **132(3)**, 321-333 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/01/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM